American International Group Inc. increased its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 7.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,304 shares of the biotechnology company’s stock after buying an additional 948 shares during the period. American International Group Inc.’s holdings in Atara Biotherapeutics were worth $294,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $132,000. DekaBank Deutsche Girozentrale bought a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $185,000. Parametric Portfolio Associates LLC increased its position in shares of Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after buying an additional 9,774 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $555,000. Finally, Swiss National Bank increased its position in shares of Atara Biotherapeutics by 9.6% in the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock worth $588,000 after buying an additional 2,500 shares in the last quarter. 81.71% of the stock is owned by institutional investors and hedge funds.
Atara Biotherapeutics, Inc. (ATRA) opened at 16.00 on Friday. Atara Biotherapeutics, Inc. has a 12 month low of $11.80 and a 12 month high of $25.73. The firm’s market capitalization is $465.74 million. The stock’s 50 day moving average price is $14.19 and its 200-day moving average price is $15.90.
COPYRIGHT VIOLATION WARNING: This article was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2017/07/23/american-international-group-inc-has-294000-stake-in-atara-biotherapeutics-inc-nasdaqatra.html.
A number of equities analysts have recently commented on the company. William Blair reissued an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Jefferies Group LLC reissued a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Canaccord Genuity reissued a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Finally, Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $25.75.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 3,600 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $17.33, for a total transaction of $62,388.00. Following the sale, the chief executive officer now directly owns 725,951 shares in the company, valued at approximately $12,580,730.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 7,200 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, April 26th. The stock was sold at an average price of $17.56, for a total value of $126,432.00. Following the sale, the chief executive officer now owns 725,951 shares in the company, valued at $12,747,699.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,808 shares of company stock worth $848,075. Company insiders own 16.10% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
